Francesca Cortese, Luisiana Stolfi, Giampaolo Luzi, Giandomenico Tarsia, Gianpaolo D'Addeo, Marilena De Francesco, Paolo Tondi, Marco Fabio Costantino
{"title":"浅静脉血栓:最新研究进展。复习一下。","authors":"Francesca Cortese, Luisiana Stolfi, Giampaolo Luzi, Giandomenico Tarsia, Gianpaolo D'Addeo, Marilena De Francesco, Paolo Tondi, Marco Fabio Costantino","doi":"10.1177/02683555251338747","DOIUrl":null,"url":null,"abstract":"<p><p>ObjectivesSuperficial venous thrombosis (SVT) is an acute thrombosis affecting the superficial venous system, characterized by inflammation of the venous wall. While much research has focused on deep vein thrombosis (DVT), SVT has historically been neglected due to its reputation as a benign and self-limiting condition.MethodsA literature search was conducted using PubMed and Google Scholar from January 2000 to December 2023, focusing on English-language publications and including original articles, systematic reviews, and randomized controlled trials. The following keywords were used in various combinations: \"superficial venous thrombosis,\" \"superficial thrombophlebitis,\" \"phlebitis,\" and \"thrombophlebitis.\" The review aimed to analyze SVT, discuss its key features, treatment approaches, and prognosis. We identified 133 potentially relevant records, of which 98 were screened in full text; 39 met our inclusion criteria (i.e., adult populations, clinical data on SVT incidence, risk factors, and treatment outcomes). A PRISMA-style flowchart illustrates the selection process and reasons for exclusion (e.g., duplication, lack of relevant endpoints).ResultsSVT is a common but often underestimated condition that can lead to complications, including pulmonary embolism. The mainstay treatment consists of anticoagulant therapy, starting with low-dose unfractionated heparin or fondaparinux as the first-line drug, progressing to oral anticoagulants at therapeutic doses in more extensive cases. The diagnosis is primarily clinical but should be confirmed by color Doppler ultrasound. Furthermore, SVT may be indicative of serious underlying conditions.ConclusionsWhile often considered benign, SVT is a deceptive pathology. If not properly diagnosed and treated, it can progress to DVT and associated complications. Additionally, SVT may signal significant systemic conditions such as malignancies, hereditary thrombophilia, and cardiovascular diseases, warranting further investigation by clinicians.</p>","PeriodicalId":94350,"journal":{"name":"Phlebology","volume":" ","pages":"2683555251338747"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Superficial vein thrombosis: State of art. A review.\",\"authors\":\"Francesca Cortese, Luisiana Stolfi, Giampaolo Luzi, Giandomenico Tarsia, Gianpaolo D'Addeo, Marilena De Francesco, Paolo Tondi, Marco Fabio Costantino\",\"doi\":\"10.1177/02683555251338747\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>ObjectivesSuperficial venous thrombosis (SVT) is an acute thrombosis affecting the superficial venous system, characterized by inflammation of the venous wall. While much research has focused on deep vein thrombosis (DVT), SVT has historically been neglected due to its reputation as a benign and self-limiting condition.MethodsA literature search was conducted using PubMed and Google Scholar from January 2000 to December 2023, focusing on English-language publications and including original articles, systematic reviews, and randomized controlled trials. The following keywords were used in various combinations: \\\"superficial venous thrombosis,\\\" \\\"superficial thrombophlebitis,\\\" \\\"phlebitis,\\\" and \\\"thrombophlebitis.\\\" The review aimed to analyze SVT, discuss its key features, treatment approaches, and prognosis. We identified 133 potentially relevant records, of which 98 were screened in full text; 39 met our inclusion criteria (i.e., adult populations, clinical data on SVT incidence, risk factors, and treatment outcomes). A PRISMA-style flowchart illustrates the selection process and reasons for exclusion (e.g., duplication, lack of relevant endpoints).ResultsSVT is a common but often underestimated condition that can lead to complications, including pulmonary embolism. The mainstay treatment consists of anticoagulant therapy, starting with low-dose unfractionated heparin or fondaparinux as the first-line drug, progressing to oral anticoagulants at therapeutic doses in more extensive cases. The diagnosis is primarily clinical but should be confirmed by color Doppler ultrasound. Furthermore, SVT may be indicative of serious underlying conditions.ConclusionsWhile often considered benign, SVT is a deceptive pathology. If not properly diagnosed and treated, it can progress to DVT and associated complications. Additionally, SVT may signal significant systemic conditions such as malignancies, hereditary thrombophilia, and cardiovascular diseases, warranting further investigation by clinicians.</p>\",\"PeriodicalId\":94350,\"journal\":{\"name\":\"Phlebology\",\"volume\":\" \",\"pages\":\"2683555251338747\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-05-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Phlebology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1177/02683555251338747\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Phlebology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1177/02683555251338747","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Superficial vein thrombosis: State of art. A review.
ObjectivesSuperficial venous thrombosis (SVT) is an acute thrombosis affecting the superficial venous system, characterized by inflammation of the venous wall. While much research has focused on deep vein thrombosis (DVT), SVT has historically been neglected due to its reputation as a benign and self-limiting condition.MethodsA literature search was conducted using PubMed and Google Scholar from January 2000 to December 2023, focusing on English-language publications and including original articles, systematic reviews, and randomized controlled trials. The following keywords were used in various combinations: "superficial venous thrombosis," "superficial thrombophlebitis," "phlebitis," and "thrombophlebitis." The review aimed to analyze SVT, discuss its key features, treatment approaches, and prognosis. We identified 133 potentially relevant records, of which 98 were screened in full text; 39 met our inclusion criteria (i.e., adult populations, clinical data on SVT incidence, risk factors, and treatment outcomes). A PRISMA-style flowchart illustrates the selection process and reasons for exclusion (e.g., duplication, lack of relevant endpoints).ResultsSVT is a common but often underestimated condition that can lead to complications, including pulmonary embolism. The mainstay treatment consists of anticoagulant therapy, starting with low-dose unfractionated heparin or fondaparinux as the first-line drug, progressing to oral anticoagulants at therapeutic doses in more extensive cases. The diagnosis is primarily clinical but should be confirmed by color Doppler ultrasound. Furthermore, SVT may be indicative of serious underlying conditions.ConclusionsWhile often considered benign, SVT is a deceptive pathology. If not properly diagnosed and treated, it can progress to DVT and associated complications. Additionally, SVT may signal significant systemic conditions such as malignancies, hereditary thrombophilia, and cardiovascular diseases, warranting further investigation by clinicians.